StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Anavex Life Sciences (AVXL) Confirms Information in July 27 Press Release Announcing Positive Results from Phase 2a Alzheimer's Trial for ANAVEX 2-73
July 29, 2016 9:22 AM
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), confirms the information in the July 27, 2016 press release ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Momentum Movers
Short Sales
Next Articles
Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients Presented at AAIC 2016
July 29, 2016 9:20 AM
Anavex Life Sciences (AVXL) Presents Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients at AAIC
July 27, 2016 1:01 PM
Anavex Presents 31-Week Efficacy Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients at AAIC 2016
July 27, 2016 1:00 PM